Evidence map›Paper›PMID 42333283›Full record

ReviewInternational journal of nanomedicine2026

Nano-Immunotherapy Targeting TAMs: Precisely Regulating TAMs to Reverse Immunosuppressive TME.

Jin-Ming Zhang, Chun-Ling Dong, Bo Li

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jin-Ming ZhangDepartment of Oral Anatomy and Physiology, Jilin Provincial Key Laboratory of Oral Biomedical Engineering, Hospital of Stomatology, Jilin University, Changchun, People's Republic of China.ORCID 0009-0005-8242-9138
Chun-Ling DongDepartment of Pulmonary and Critical Care Medicine, Second Hospital, Jilin University, Changchun, People's Republic of China.ORCID 0000-0002-6389-5011
Bo LiDepartment of Oral Anatomy and Physiology, Jilin Provincial Key Laboratory of Oral Biomedical Engineering, Hospital of Stomatology, Jilin University, Changchun, People's Republic of China.ORCID 0000-0002-6005-6351

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Given the crucial role of tumor-associated macrophages (TAMs) in cancer development, nano-immunotherapy targeting TAMs represents a pivotal strategy for reversing the immunosuppressive tumor microenvironment (TME) and inhibiting cancer progression. Nano-drug delivery systems have evolved into multimodal platforms that utilize multi-drug synergy and integrated physical energy interventions, showing considerable potential for enhancing drug targeting and biocompatibility. The core objective of TAM-targeted nano-immunotherapy lies in the precise regulation and functional remodeling of TAMs, as well as the synergistic reversal of the immunosuppressive TME. This review addresses the knowledge gaps and challenges in nano-immunotherapy targeting TAMs and explores recent advances in TAM-targeted immunotherapy using various strategies and nanocarriers, with particular emphasis on the relevant cell surface receptors and downstream signaling pathways. Nano-immunotherapeutic strategies targeting TAMs include reprogramming TAMs, influencing TAM polarization, regulating TAM-secreted mediators, inducing TAM exhaustion, enhancing TAM phagocytosis, modulating TAM metabolism, inhibiting TAM recruitment, and blocking PD-L1 expression on TAMs. The innovations of nanocarriers involve the entire chain intelligent design from inorganic nanocrystals, organic polymers to organic-inorganic hybrid systems, and the precise "Trojan horses" constructed using biodegradable polymers and biomimetic membrane vesicles. Intelligent nanorobots targeting TAMs, as autonomous diagnostic and therapeutic systems integrating sensing, decision-making, and execution, represent an effective approach to enhancing the precision and intelligence of anti-tumor strategies.

Indexed as

ImmunotherapyNanoparticlesNeoplasmsTumor-Associated MacrophagesTumor MicroenvironmentAnimalsDrug Delivery SystemsHumansNanomedicineNanoparticle Drug Delivery SystemNanoparticle Drug Delivery Systemcancerimmunotherapynanocarriertargetingtumor-associated macrophages

Identifiers

PMID42333283
PMCPMC13283409

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.